Hawaii 2022 Regular Session

Hawaii Senate Bill SB738 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.B. NO. 738 THIRTY-FIRST LEGISLATURE, 2021 STATE OF HAWAII A BILL FOR AN ACT relating to schedule i substances. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	THE SENATE S.B. NO. 738
4	4	THIRTY-FIRST LEGISLATURE, 2021
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.B. NO.
10	10
11	11	738
12	12
13	13	THIRTY-FIRST LEGISLATURE, 2021
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	relating to schedule i substances.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows: "§321- Designated treatment centers; psilocybin. (a) The department shall establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn. (b) The department shall adopt rules in accordance with chapter 91 necessary to implement this section." SECTION 2. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (d) to read as follows: "(d) Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine (AET); (2) 2,5-dimethoxy-4-ethylamphetamine (DOET); (3) 2,5-dimethoxyamphetamine (2,5-DMA); (4) 3,4-methylenedioxy amphetamine; (5) 3,4-methylenedioxymethamphetamine (MDMA); (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA); (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE); (8) 5-methoxy-3,4-methylenedioxy-amphetamine; (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA); (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus); (11) 3,4,5-trimethoxy amphetamine; (12) Bufotenine; (13) 4-methoxyamphetamine (PMA); (14) Diethyltryptamine; (15) Dimethyltryptamine; (16) 4-methyl-2,5-dimethoxy-amphetamine; (17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate); (18) Ibogaine; (19) Lysergic acid diethylamide; (20) Marijuana; (21) Parahexyl; (22) Mescaline; (23) Peyote; (24) N-ethyl-3-piperidyl benzilate; (25) N-methyl-3-piperidyl benzilate; [(26) Psilocybin; (27) Psilocyn; (28)] (26) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy); [(29)] (27) Ethylamine analog of phencyclidine (PCE); [(30)] (28) Pyrrolidine analog of phencyclidine (PCPy, PHP); [(31)] (29) Thiophene analog of phencyclidine (TPCP; TCP); [(32)] (30) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion; [(33)] (31) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion; [(34)] (32) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers; [(35)] (33) N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers; [(36)] (34) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers; [(37)] (35) Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers; [(38)] (36) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers; [(39)] (37) Salvia divinorum; [(40)] (38) Salvinorin A; [(41)] (39) Divinorin A; [(42)] (40) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT); [(43)] (41) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); [(44)] (42) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); [(45)] (43) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); [(46)] (44) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); [(47)] (45) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); [(48)] (46) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); [(49)] (47) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); [(50)] (48) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); [(51)] (49) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); [(52)] (50) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5); [(53)] (51) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and [(54)] (52) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)." SECTION 3. (a) The governor shall establish and convene a psilocybin review panel to review and assess the effects of this Act. (b) The review panel shall consist of: (1) The governor or the governor's designee, who shall serve as the chairperson of the panel; (2) The director of health or the director's designee; (3) The director of public safety or the director's designee; (4) The chairperson of the house of representatives standing committee on corrections, military, and veterans or the chairperson's designee; (5) The chairperson of the house of representatives standing committee on health, human services, and homelessness or the chairperson's designee; (6) The chairperson of the senate standing committee on health or the chairperson's designee; and (7) The chairperson of the senate standing committee on public safety, intergovernmental, and military affairs or the chairperson's designee. (c) The review panel shall submit a report to the legislature, including any proposed legislation, no later than twenty days prior to the convening of the regular sessions of 2022, 2023, 2024, 2025, and 2026. (d) The review panel shall cease to exist on July 1, 2026. SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored. SECTION 5. This Act shall take effect upon its approval. INTRODUCED BY: _____________________________
48	48
49	49	SECTION 1. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows:
50	50
51	51	"§321- Designated treatment centers; psilocybin. (a) The department shall establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn.
52	52
53	53	(b) The department shall adopt rules in accordance with chapter 91 necessary to implement this section."
54	54
55	55	SECTION 2. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (d) to read as follows:
56	56
57	57	"(d) Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
58	58
59	59	(1) Alpha-ethyltryptamine (AET);
60	60
61	61	(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
62	62
63	63	(3) 2,5-dimethoxyamphetamine (2,5-DMA);
64	64
65	65	(4) 3,4-methylenedioxy amphetamine;
66	66
67	67	(5) 3,4-methylenedioxymethamphetamine (MDMA);
68	68
69	69	(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
70	70
71	71	(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
72	72
73	73	(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
74	74
75	75	(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
76	76
77	77	(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
78	78
79	79	(11) 3,4,5-trimethoxy amphetamine;
80	80
81	81	(12) Bufotenine;
82	82
83	83	(13) 4-methoxyamphetamine (PMA);
84	84
85	85	(14) Diethyltryptamine;
86	86
87	87	(15) Dimethyltryptamine;
88	88
89	89	(16) 4-methyl-2,5-dimethoxy-amphetamine;
90	90
91	91	(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
92	92
93	93	(18) Ibogaine;
94	94
95	95	(19) Lysergic acid diethylamide;
96	96
97	97	(20) Marijuana;
98	98
99	99	(21) Parahexyl;
100	100
101	101	(22) Mescaline;
102	102
103	103	(23) Peyote;
104	104
105	105	(24) N-ethyl-3-piperidyl benzilate;
106	106
107	107	(25) N-methyl-3-piperidyl benzilate;
108	108
109	109	[(26) Psilocybin;
110	110
111	111	(27) Psilocyn;
112	112
113	113	(28)] (26) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
114	114
115	115	[(29)] (27) Ethylamine analog of phencyclidine (PCE);
116	116
117	117	[(30)] (28) Pyrrolidine analog of phencyclidine (PCPy, PHP);
118	118
119	119	[(31)] (29) Thiophene analog of phencyclidine (TPCP; TCP);
120	120
121	121	[(32)] (30) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;
122	122
123	123	[(33)] (31) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;
124	124
125	125	[(34)] (32) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
126	126
127	127	[(35)] (33) N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;
128	128
129	129	[(36)] (34) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;
130	130
131	131	[(37)] (35) Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers;
132	132
133	133	[(38)] (36) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers;
134	134
135	135	[(39)] (37) Salvia divinorum;
136	136
137	137	[(40)] (38) Salvinorin A;
138	138
139	139	[(41)] (39) Divinorin A;
140	140
141	141	[(42)] (40) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);
142	142
143	143	[(43)] (41) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
144	144
145	145	[(44)] (42) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
146	146
147	147	[(45)] (43) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
148	148
149	149	[(46)] (44) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
150	150
151	151	[(47)] (45) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
152	152
153	153	[(48)] (46) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
154	154
155	155	[(49)] (47) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
156	156
157	157	[(50)] (48) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
158	158
159	159	[(51)] (49) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
160	160
161	161	[(52)] (50) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
162	162
163	163	[(53)] (51) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and
164	164
165	165	[(54)] (52) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."
166	166
167	167	SECTION 3. (a) The governor shall establish and convene a psilocybin review panel to review and assess the effects of this Act.
168	168
169	169	(b) The review panel shall consist of:
170	170
171	171	(1) The governor or the governor's designee, who shall serve as the chairperson of the panel;
172	172
173	173	(2) The director of health or the director's designee;
174	174
175	175	(3) The director of public safety or the director's designee;
176	176
177	177	(4) The chairperson of the house of representatives standing committee on corrections, military, and veterans or the chairperson's designee;
178	178
179	179	(5) The chairperson of the house of representatives standing committee on health, human services, and homelessness or the chairperson's designee;
180	180
181	181	(6) The chairperson of the senate standing committee on health or the chairperson's designee; and
182	182
183	183	(7) The chairperson of the senate standing committee on public safety, intergovernmental, and military affairs or the chairperson's designee.
184	184
185	185	(c) The review panel shall submit a report to the legislature, including any proposed legislation, no later than twenty days prior to the convening of the regular sessions of 2022, 2023, 2024, 2025, and 2026.
186	186
187	187	(d) The review panel shall cease to exist on July 1, 2026.
188	188
189	189	SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
190	190
191	191	SECTION 5. This Act shall take effect upon its approval.
192	192
193	193
194	194
195	195	INTRODUCED BY: _____________________________
196	196
197	197	INTRODUCED BY:
198	198
199	199	_____________________________
200	200
201	201
202	202
203	203
204	204
205	205	Report Title: Psilocybin; Psilocyn; Therapeutic Administration; Decriminalization Description: Removes psilocybin and psilocyn from the list of Schedule I substances. Requires the Department of Health to establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn. Establishes a review panel to review and assess the effects of this measure. The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
206	206
207	207
208	208
209	209
210	210
211	211	Report Title:
212	212
213	213	Psilocybin; Psilocyn; Therapeutic Administration; Decriminalization
214	214
215	215
216	216
217	217	Description:
218	218
219	219	Removes psilocybin and psilocyn from the list of Schedule I substances. Requires the Department of Health to establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn. Establishes a review panel to review and assess the effects of this measure.
220	220
221	221
222	222
223	223
224	224
225	225
226	226
227	227	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.